3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Melanoma
5
Neoplasms
4
Thyroid Neoplasms
3
Neurofibromatosis 1
3
Lung Neoplasms
3
Uveal Melanoma
2
Thyroid Cancer, Papillary
2
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Thymoma
1
Solid Tumours
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroma, Acoustic
1
Neurofibrosarcoma
1
Neurofibromatosis 2
1
Neurofibroma, Plexiform
1
Neuroblastoma
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Meningioma
1
Interventions
vandetanib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Differentiated Thyroid Cancer
×
AZD 6244
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts